Introduction

All cancer tissue phenotypes are initiated by deregulated signalling mechanisms in cancer cells. Signalling mechanisms are also the largest target mechanism entity for targeted cancer therapies. Recent data also strongly indicate that cancer therapy resistance is initiated by non-genetic signaling rewiring via post-translational regulation of proteins involved in signalling networks and transcriptional gene regulation.

However, regardless of decades of research, our global understanding of how cancer cell signalling circuits are controlled, and how they determine cancer progression and therapy resistance, is still far from complete. This conference will focus on basic mechanisms controlling cancer cell signalling circuits at the transcriptome, proteome and phosphoproteome levels as well as emerging concepts in cancer cell signalling. 

Register now

Target audience:

Scientists in academia and industry who are interested in most recent developments in non-genetic signalling mechanisms and their roles in cancer progression and therapy resistance. The conference will focus on the mechanistic aspects of post translational and transcriptional regulation of cancer cell signalling, as well as OMICS-based understanding of cancer cell signalling circuits and thereby opens novel insights also to development of novel cancer therapies and diagnostics. 

Topics to be covered:

• Kinases and phosphatases
• Post-translational protein regulatory switches 
• Non-genetic signalling rewiring 
• Proteogenomic signal integration
• RNA biology in cancer 
• Therapy tolerance and resistance

Scientific Programme Committee:

• Jukka Westermarck (Chair), Turku Bioscience Centre, University of Turku, Finland
• Chiara Ambrogio, University of Torino, Italy
• Yaara Oren, Tel Aviv University, Israel

Lay summary of the conference topic:

All cancers share certain characteristics and one of them is that the intracellular mechanisms regulating cancer cell behaviour are deregulated. These so called signalling mechanism are also the largest target mechanism entity for targeted cancer therapies, and thereby their understanding is not only vital for better basic understanding of cancer as a disease, but also for development of new approaches for cancer therapies and diagnostics.  However, regardless of decades of research, our global understanding of how cancer cell signalling circuits are controlled, and how they determine cancer progression and therapy resistance is still far from complete. This conference will focus on basic mechanisms controlling cancer cell signalling circuits with a goal to share the most recent knowledge among the researchers on the field and beyond. 

Follow us on Bluesky for updates @helloeacr